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Genetic association studies of leprosy cohorts across the world have identiﬁed numerous polymorphisms which alter susceptibility
and outcome to infection with Mycobacterium leprae. As expected, many of the polymorphisms reside within genes that encode
components of the innate and adaptive immune system. Despite the preponderance of these studies, our understanding of the
mechanisms that underlie these genetic associations remains sparse. Toll-like receptors (TLRs) have emerged as an essential
family of innate immune pattern recognition receptors which play a pivotal role in host defense against microbes, including
pathogenic strains of mycobacteria. This paper will highlight studies which have uncovered the association of speciﬁc TLR gene
polymorphisms with leprosy or tuberculosis: two important diseases resulting from mycobacterial infection. This analysis will
focusonthepotentialinﬂuencethesepolymorphicvariantshaveonTLRexpressionandfunctionandhowalteredTLRrecognition
or signaling may contribute to successful antimycobacterial immunity.
1.Introduction
Mycobacterium leprae is an evolutionarily ancient pathogen
of historical and worldwide prevalence. Identiﬁed in 1873 by
Gerhard Armauer Hansen as the causative agent of leprosy,
these fastidious, intracellular bacilli have been studied exten-
sively for their complex pathogenesis and host interactions.
Cellular tropisms for M. leprae principally include tissue-
resident macrophages, especially in the skin and upper respi-
ratory tract, and Schwann cells of the peripheral nervous sys-
tem. The intricate spectrum of clinical manifestations which
exists for the disease is illustrated by two polar responses,
tuberculoid or lepromatous leprosy, and various intermedi-
a t eo rb o r d e r l i n ef o r m s[ 1]. The tuberculoid manifestation
is typically less severe and is characterized by lower leprosy
burden and containment of bacilli by distinct granulomas.
This form exhibits few hypopigmented skin lesions and
scarce thickening of peripheral nerves, leading to loss of
sensation in extremities and the skin. Lepromatous leprosy
constitutes the opposite polar reaction to infection where
high, diﬀuse bacterial load can cause extensive skin plaques,
nodules and thickening, and numerous anesthetic zones due
to pervasive peripheral nerve damage.
Surprisingly little genotypic variation exists between
strains of M. leprae, a fact inconsistent with the high degree
of variability in virulence and disease penetrance between
individuals. This suggests that success of infection and
leprosy progression rests in large part upon the patient’s
immune response and genetic complement. Strikingly, the
variable spectrum of leprosy outcome correlates tightly with
the balance of T-helper-cell-mediated immunity responding
to M. leprae infection. A robust TH1 host response, featuring
appreciable production of interferon-gamma (IFNγ)a n d
interleukin-12 (IL-12) along with macrophage and CD4+
T cell activation, is typically represented in the contained,
tuberculoid form. Alternatively a strong TH2 response,
characterized by an intense but nonprotective humoral
reaction,inadditiontohighIL-4andIL-10release,coincides
with the lepromatous manifestation. A system of regulation
controlling such a delicate balance is certain to be complex,
but undoubtedly must begin with pathogen recognition at
the sites of host inoculation.2 Journal of Tropical Medicine
The innate immune system provides an immediate
means of surveillance for invading microorganisms and im-
portantly, for a disease such as leprosy, plays a key role in
initializing the type of adaptive strategy that the host will
use to respond to infection. Pattern recognition receptors
(PRRs)are pivotal for innate sensing of conserved microbial-
associated molecules indicative of infection in the extracel-
lular milieu. Amongst the PRRs is a class of type-1 inte-
gral membrane proteins, the ten-member Toll-like receptor
family, whose extracellular domains recognize a diverse array
of such microbial agonists. TLRs are expressed by a variety
of leukocytes and solid tissue cell types, with the highest
levels primarily displayed by cells of myeloid lineage such
as monocytes, macrophages, and dendritic cells. However,
TLR subsets are also expressed in lymphocytes, epithelium,
endothelium, ﬁbroblasts, and even Schwann cells. Upon
ligand binding, the TLRs initiate a signal cascade which
ultimately activates NFκB-regulated genes, most notably
encodingproinﬂammatorycytokineandchemokines,aswell
as the costimulatory molecules required for T-cell activation.
M. leprae and other mycobacterial species such as M.
tuberculosis are rich in agonists for several members of the
TLR family, including TLR1, 2, 4, 6, and 9.
Genetic association studies have identiﬁed a number of
singlenucleotidepolymorphisms(SNPs)inTLRgeneswhich
associate with susceptibility or resistance to bacterial and
viral infection. Due to the high relevance of host genetic
factors in the outcome of M. leprae infection, decades of
research have been devoted to identifying key polymor-
phisms which associate strongly with the predisposition to
clinical leprosy manifestation, spontaneous clearance, and to
the spectrum of disease progression. This paper will examine
speciﬁc TLR polymorphisms which are associated with M.
leprae and M. tuberculosis infection, with a focus on the
potential mechanistic basis for their eﬀects on pathogenesis
and host response.
2.TLR-MediatedRecognition of Mycobacteria
2.1. TLR1/2. The majority of TLRs (TLR3, 4, 5, 7, 8,
and 9) signal via homodimerization in the presence of
agonist binding. Members of the TLR2 subfamily, which
includes TLR1, 2, 6, and 10, are unique in their ability to
form heterodimeric complexes which sense an extremely
diverse group of microbial molecules. TLR1 heterodimerizes
with TLR2 to recognize primarily triacylated lipoproteins
displayed by Gram-positive, Gram-negative, and acid-fast
bacteria [2–4]. This receptor pair is also capable of detecting
glycolipids, glycoproteins, lipopeptides, lipoteichoic acids,
a n df u n g a lc e l lw a l lc o m p o n e n t s[ 3–8]. Interestingly, the
cell wall and membrane of mycobacteria are especially rich
in TLR1/2 agonists. The lipoglycans lipomannan (LM) and
mannose or arabinose-capped lipoarabinomannan (Man-
LAM and AraLAM) are major virulence factors in mycobac-
terialspecies.ManLAMandAraLAMinparticulararepotent
TLR1/2 agonists and have been shown to contribute both
to macrophage activation and immunomodulation of host
responses[5,8].Thesemoleculesbehaveinlargepartasscav-
engersofreactiveoxygenspeciesdeployedbythephagosomal
oxidative burst [9]. In addition, stimulation of macrophages
with puriﬁed M. leprae and M. tuberculosis LAM molecules
has been shown to decrease IFNγ-inducible microbial killing
by macrophages, reduce T-cell proliferation and activation,
and inhibit protein kinase C, a key transduction molecule in
IFNγ and respiratory burst signaling [9–11].
Although TLR2 has the ability to dimerize with multiple
TLR coreceptors, TLR1/2 heterodimers are the primary
sensors by which immune cells recognize mycobacterial
lipoproteins [4, 6]. Signiﬁcant examples of such mycobacte-
rial agonists include the M. leprae and M. tuberculosis 19kDa
lipoprotein orthologs, ML1966 and LpqH [12]. These
membrane-anchored proteins possess adhesin properties
and serve as major mycobacterial surface antigens [13].
Like the cell wall lipoglycans, LpqH in particular provides
robust immunosuppressive functions. The impressive ability
of these triacylated lipoproteins to deactivate macrophages
has been well characterized and shown to be dependent
on engagement of TLR2 [14–23]. The M. leprae annotated
genomic sequence predicts 31 diﬀerent lipoprotein genes,
includingtheenzymaticmachineryforligationofacylchains
[12]. Orthologous partners for all of these genes exist in M.
tuberculosis, which possesses an additional 60 genes encod-
ing putative lipoproteins. In addition to the well-studied
19kDa antigen, M. leprae also encodes a 33kda (ML0603)
lipoprotein with TLR2 immunostimulatory activity [12].
It is conceivable that many of the triacylated lipoproteins
displayed by both leprosy and tuberculosis bacilli could
signal via TLR1/2 heterodimers and may possess similarly
immunosuppressivefunctionstothoseofthe19kDaantigen.
Nonlipidated molecules derived from mycobacteria are
also capable of binding and signaling through TLR1/2.
The 6kDa early secreted antigenic target (ESAT-6) of
M. tuberculosis is a highly potent CD4+ T-cell antigen and
is absent in most nontuberculosis complex mycobacteria
[24, 25]. A commonly used diagnostic test for TB, approved
by the FDA in 2005, is based upon whole blood stimulation
w i t hp u r i ﬁ e dE S A T - 6i na nI F N γ release assay. Unlike
classical proinﬂammatory TLR agonists, it has been shown
that ESAT-6 engages TLR2 in a way that inhibits MyD88-
dependent TLR signaling including activation of NFκBa n d
interferon regulatory factors [26]. M. leprae possesses an
ESAT-6 ortholog with 36% identity, ML0049, and both
monocytes and T cells from leprosy patients respond to
L-ESAT-6 by secreting IFNγ [27]. At this time no direct
evidence is available to support an immunosuppressive role
for ML0049 similar to that of ESAT-6.
2.2.TLR4. WhileinnateimmuneresponsestobothM.leprae
and M. tuberculosis rely heavily on TLR1/2 stimulation by
various cell wall components, TLR4 has also been shown to
play a role in detecting mycobacteria. The classical ligand
for TLR4 is lipopolysaccharide (LPS), derived from the outer
cell membrane of Gram-negative bacteria. Despite the fact
that LPS is absent from mycobacterial membranes, studies in
transfected cells and murine macrophages have shown that
M. leprae and M. tuberculosis are both recognized by TLR4
[5, 6]. For M. tuberculosis, this eﬀect was linked to MD-2-
mediated TLR4 recognition of secreted heat shock proteinJournal of Tropical Medicine 3
65 (HSP-65) and chaperonin 60 protein [28, 29]. Another
secreted tuberculosis protein, the adhesin heparin-binding
hemagglutinin (HBHA), was found to bind TLR4, induce
maturation, and activate proinﬂammatory cytokine secre-
tion in dendritic cells [30]. M. leprae encodes orthologs of
HSP60, HSP65, and HBHA, but no studies have examined
whether these proteins possess similar TLR4 stimulating
qualities to those of M. tuberculosis.I th a sb e e nr e p o r t e d
howeverthatLPSbindingbyTLR4canbeblockedwithheat-
killed M. leprae, inhibiting monocyte secretion of IL-1β and
IL-6 [31].
2.3.TLR9. TLR9mediatesrecognitionofunmethylatedCpG
elements in viral and bacterial DNA, a motif relatively rare
in vertebrate genomes [32, 33]. Unlike TLR1, 2, and 4,
which traﬃc to the cell surface, TLR9 is predominantly
expressed intracellularly in the endoplasmic reticulum [33].
Upon pathogen stimulation, TLR9 localizes to endosomal
compartments, where the receptor gains access to genomic
DNA released from the degradation of phagocytized bac-
teria or internalized virus [34]. Primary human monocyte-
derived macrophages and murine dendritic cells respond to
stimulation with CpG DNA derived from various strains of
M. tuberculosis (H37Rv and H37Ra) and M. bovis (wildtype
and BCG) by increasing transcription of TNFα and IFNα
[35, 36]. Interestingly, DNA from the attenuated strains
induces a much more vigorous TNFα response than DNA
from virulent mycobacteria [4].
3. TLR Polymorphisms
Given the importance of TLRs in mediating host responses
to pathogenic mycobacteria, it is not surprising that single
nucleotide polymorphisms eﬀecting expression or function
ofthesereceptorsinﬂuenceshostsusceptibilitytoleprosyand
tuberculosis.
3.1. TLR1. A SNP involving a thymine to guanine transver-
sion (T1805G) in TLR1 results in a nonsynonymous sub-
stitution at amino acid position 602 (I602S), a position
residing in the cytoplasmic region proximal to the receptor’s
transmembrane domain [37, 38]. Although western blotting
andintracellularstainingillustrateequivalentproteinexpres-
sion of each variant, both transfection and primary human
monocyte studies reveal a traﬃcking deﬁciency for TLR1
602S, causing the receptor to be absent from the plasma
membrane[38].Intransfectedcelllinesandmonocytesfrom
TLR1 602S/S homozygotes, the subsequent lack of surface
TLR1 602S induces a state of hyporesponsiveness to TLR1/2
agonists, including bacterial lipoproteins and synthetic tria-
cylated lipopeptides [37, 38]. These results serve to highlight
the importance of TLR localization in receptor function.
GeneticassociationstudiesofleprosyhaveincludedDNA
samplesfromdiversepopulationsacrosstheworld,including
individuals of Eastern Asian, African American, Hispanic,
Nepalese, Turkish, and Caucasian backgrounds. Notably, the
allelicdistributionofTLR1I602Svariesgreatlydependingon
racial ancestry. For example, Caucasian individuals possess
the 602I allele at ∼25% and the 602S allele at ∼75%,
whileAfricanAmericanindividualspossessareciprocalallele
frequency of ∼75/25 percent for I/S [38, 39]. Hispanic,
Turkish, and Nepalese individuals have I/S ratios of ∼70/30,
57/43, and ∼94/6 percent, respectively [38–40]. The TLR1
602S allele appears to be virtually absent in East Asian
individuals with a 602I allele frequency of >99% [38].
Peripheral blood mononuclear cells from TLR1 602S/S
individuals were shown to have greatly diminished cytokine
production when stimulated with whole irradiated M. leprae
and M. tuberculosis,a sw e l la sm e m b r a n ea n dc e l lw a l l
fractions [37–39]. It would therefore be expected that indi-
viduals homozygous for TLR1 602S would have increased
susceptibility to mycobacterial infection. However, several
disease association studies have revealed a protective role for
the deﬁcient TLR1 602S variant against the development of
both clinical leprosy and tuberculosis [38–41]. The study
performedbyJohnsonetal.observedthatacohortofTurkish
leprosy patients had a signiﬁcantly higher allele frequency
for TLR1 602I versus healthy controls. Conversely, the TLR1
602S allele was signiﬁcantly underrepresented amongst lep-
rosy patients, with an odds ratio for infection of 0.48 (P<
0.05) among TLR1 602S/S homozygotes [38].
TH2-directedlepromatousor borderline formsofleprosy
are potentially unstable disease states and may quickly revert
to a TH1 type adaptive response during a so-called reversal
reaction.Thiscanresultinasuddenandexacerbatedincrease
in acute T-cell-mediated immunity and create more intense
tuberculoidsymptomsalongwithlocaltissuedamage.Misch
et al. observed that the TLR1 602S allele confers protection
against leprosy reversal reaction (OR = 0.51, P = 0.01) [39].
TLR1 I602S also has been shown to inﬂuence risk of tuber-
culosis. Ma et al. observed a signiﬁcant increase in the rate of
extrapulmonary TB infection in African American patients
possessing the 602I/I genotype (OR = 2.5, P<0.001) [40].
Striking evidence of this polymorphism’s role in leprosy was
established when an extensive and unbiased genome-wide
array of 2092 genes in 1500 individuals identiﬁed TLR1 602S
(OR = 0.31, P<0.001) as one of two alleles that aﬀorded
the greatest protection against leprosy, the other being the
MHCII allele HLA-DRB1/DQA1 (OR = 0.43, P<0.001)
[41]. A second polymorphism in TLR1, N248S (A743G), is
in strong linkage disequilibrium with the TLR1 602I allele
which may explain the ﬁnding, observed in a Bangladesh
cohort of leprosy patients, that M. leprae infection associates
with the TLR1 248S/S genotype (OR = 1.34, P = 0.02) [37,
39, 42].
3.2.TLR2. Aninsertion/deletionpolymorphismintheTLR2
promoter lies at position –196 to –174bp upstream of the
start codon. This polymorphism has been studied in the
context of TLR2 expression in both asthma and hepatitis C
infection [43, 44]. An in vitro reporter construct carrying the
deletion allele of the TLR2 promoter induces lower luciferase
activity than the insertion allele, suggesting that the former
possesses inherently reduced transcriptional activity [44]. In
addition, primary human monocytes from individuals car-
rying the deletion allele produce signiﬁcantly less IL-8 upon
stimulation with peptidoglycan [43]. A subsequent disease4 Journal of Tropical Medicine
association study of Caucasian (OR = 0.41, P ≤ 0.001) and
African (Guinea-Bissau) (OR = 0.70, P = 0.02) tuberculosis
cohorts revealed protection via homozygosity for the fully
functional insertion allele [45].
A microsatellite marker located between –162 and
–100bp in the promoter region of TLR2 contains two adja-
cent variable number tandem repeats of CT and TG which
vary in length between 280–290bp [46, 47]. An investigation
of Ethiopian leprosy patients by Bochud et al. revealed a
lower frequency of the 290bp repeat allele in disease cases
versus healthy controls (OR = 0.62, P = 0.02) [46]. In
addition, a 288bp allele was observed less frequently in lep-
romatous versus tuberculoid leprosy patients (OR = 0.49,
P = 0.02). However, this same allele was also shown to
greatly increase susceptibility to reversal reaction (OR =
5.83, P = 0.001) in a subgroup of patients which had been
followedfor8additionalyears[46].Usinganinvitroreporter
assay, Yim et al. revealed that variability in the number of
microsatellite repeats eﬀected TLR2 promoter function in
response to cytokine stimulation [47].
NophenotypiceﬀectsonTLR2functionhavebeenlinked
to a synonymous SNP (N199N, C597T) in the extracellular
domainofthisreceptor.However,the8-yearleprosyreaction
followed up by Bochud et al. identiﬁed a protective role for
TLR2 597T against reversal reaction (OR = 0.34, P = 0.002)
[46]. This polymorphism was also shown to be highly rele-
vant in a Vietnamese cohort of TB patients where progres-
sion of disease was more than twofold higher and dissemi-
nation of bacilli to the brain was 3-fold higher in individuals
homozygous for the 597C allele [48].
The G2258A SNP (R753Q) in the cytoplasmic domain of
TLR2 has been well characterized as a functionally deﬁcient
variant with reduced responses to bacterial lipoproteins and
synthetic di- and triacylated lipopeptides [49, 50]. Most
reports on TLR2 R753Q have shown inhibition of signaling
inresponsetoBorreliaburgdorferilipoproteins,suchasOspA
andwholecelllysates.Onereportobservedalowerfrequency
of TLR2 753Q in Lyme disease patients than healthy controls
(OR = 0.39, P = 0.033) and an even stronger protective
eﬀectwasconferredinlatestageLymediseasepatients(OR =
0.16, P = 0.018) [50]. Interestingly, the converse result was
obtained when a Turkish cohort of tuberculosis patients was
genotyped for the TLR2 polymorphism. In this study, the
risk of developing tuberculosis was increased over 6-fold
for TLR2753Q/Q individuals and 1.6-fold for heterozygotes
[51]. Another study of Turkish pediatric patients also associ-
ated the TLR2 R753Q heterozygotes with TB, citing an over
5-fold increased risk of infection (OR = 5.05, P ≤ 0.001)
[52]. Taken together these results indicate that a functionally
deﬁcient TLR2 variant plays opposite roles in two diﬀerent
infectious diseases: protection in the context of Lyme disease
and susceptibility in the context of TB. Although no disease
association studies have been performed between TLR2
R753Q and leprosy, it would be very interesting to see if the
results observed in the context of TB would also extend to
M. leprae.
3.3. TLR4. Numerous studies of two TLR4 polymorphisms,
D299G (G896A) and T399I (C1196T), have revealed in-
creased risk of infection with several Gram-negative organ-
isms as well as septic shock [53–55]. These SNPs, which alter
amino acids in the extracellular domain of TLR4, appear to
aﬀect receptor function depending upon the experimental
system under investigation. Some studies have reported a
decrease in LPS-induced IL-12 and IL-10 in asthma patients,
reduced cytokine secretion in an inhaled LPS human model,
and inhibited signaling in cell-based transfection models
[56–58]. However, other studies have found no functional
deﬁcits exhibited by primary human monocytes and PBMCs
obtained from individuals who are either heterozygous or
homozygous for these TLR4 variants [59–61].
Similar to TLR2, deﬁcient TLR4 function is generally
associated with increased susceptibility to mycobacterium
infection. For example, a signiﬁcant increase in the fre-
quency of the TLR4 299G allele was observed in pul-
monary tuberculosis patients in an Asian Indian cohort
(OR = 2.1, P = 0.001),withhighestbacillaryloadsobserved
in homozygous individuals [62]. Other studies in HIV/TB
coinfected patients indicate that 299G is a risk factor for
active tuberculosis in Mediterranean Caucasians (OR = 2.0)
and Tanzanian patients (OR = 2.8, P = 0.06), but at bor-
derline statistical signiﬁcance [63, 64]. No statistically signif-
icant ﬁndings were associated with TLR4 T399I for TB [62–
64]. In contrast to M. tuberculosis,ap r o t e c t i v er o l ef o rT L R 4
D299G has been identiﬁed in association with M. leprosy
infection. Bochud et al. examined an Ethiopian population
and observed lower frequencies of TLR4 D299G (OR = 0.34,
P<0.001) and T399I (OR = 0.16, P<0.001) among lep-
rosy patients [31]. Conversely, another investigation found
TLR4 D299G in a Malawi cohort of leprosy patients aﬀorded
no protection, although their cohort was half the size of the
previous study [64].
3.4. TLR9. Velez et al. investigated the prevalence of several
TLR9 polymorphisms in tuberculosis patients of Caucasian,
African American, and African (Guinea-Bissau) descent
[45]. No functional studies have been performed examining
the eﬀects of these polymorphisms on TLR9 signaling. How-
ever, two of these gene-ﬂanking polymorphisms, rs352139
and rs5743836, appear to confer protection to TB. rs352139
was observed less frequently in Caucasian (OR = 0.53,
P = 0.017) and African American (OR = 0.58, P = 0.029)
TB patients, while rs5743836 provided protection in African
Americans (OR = 0.54, P = 0.024) and in Caucasians
(OR = 0.50, P = 0.015) [45]. No statistically signiﬁcant
reduction in risk was associated with members of the
Guinea-Bissau cohort.
4. Subversionof TLR Signalingby Mycobacteria
Based upon the established role of TLRs in host defense,
polymorphisms which negatively aﬀect receptor function
would be expected to increase susceptibility and worsen out-
comes to infection. This generality holds true for a number
of TLR polymorphisms in various infectious disease settings
and simply reﬂects the host’s inability to properly recognize
and respond to bacterial agonists. However, a number ofJournal of Tropical Medicine 5
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Figure 1: Stimulation of macrophage TLRs by bacterial products activates NFκB which drives transcription of interleukin-12, along with
other cytokines and chemokines that subsequently recruit and instruct T cells. Secreted IL-12 stimulates T cells to produce IFNγ, which
serves to further stimulate the macrophage. Activation of macrophages by IFNγ leads to induction of transcription factors such as STAT1
and CBP, which facilitate production of transactivators, including CIITA. This results in the transcription of multiple IFNγ-regulated genes,
including MHCII, CD86, and CD64. MHCII is required for antigen presentation and, along with CD86, is used by macrophages to activate
CD4+ T-helper cells. Antibody-opsonized particles are recognized by the phagocytic receptor, CD64, which binds the Fc portion of IgG.
TLR1 602I traﬃcs to the cell surface where it forms heterodimers with TLR2 to sense microbial agonists. Binding of the mycobacterial
19kDa lipoprotein to TLR1/2 has been shown to block STAT1-CBP activity, thereby dampening the induction of IFNγ-regulated genes. It is
possible that the traﬃcking-deﬁcient TLR1 602S allele (dashed lines) confers protection against leprosy and TB by preventing the subversion
of IFNγ signaling by these mycobacterial agonists.
functionally deﬁcient polymorphisms in TLR1 and TLR4
have been found to confer protection to mycobacterial
infection. This ﬁnding suggests that, during the course of
evolution, mycobacteria have subverted the TLR system in
ways that are advantageous to establishing and maintaining
infection.Muchoftheexperimentalevidencesupportingthis
idea is provided below.
4.1. Adaptive Response. Several studies have revealed that
prolonged mycobacterial stimulation via TLR1/2 causes
macrophages to become refractory to IFNγ (Figure 1)[ 14–
23]. IFNγ, a type-2 interferon primarily secreted by T cells
and natural killer cells, is a TH1-skewing cytokine essential
to the containment of mycobacterial infection. This secreted
dimericglycoproteinisaclassicalactivatorofinnateimmune
eﬀectors and plays a key role in the induction of macrophage
microbicidal functions, including phagolysosome matura-
tion and oxidative burst. In addition, IFNγ facilitates a
priming function by upregulating the cellular machinery
required for antigen presentation, phagocytosis, and T-cell
costimulation. Mice deﬁcient in cytokine production or the
IFNγ receptor develop disseminating and ultimately fatal
mycobacterial disease [65]. Also, a human mutation linked
toIFNγ signalingassociateswithsusceptibilitymycobacterial
disease and disseminated infection following vaccination
with the Calmette-Gu` erin bacillus strain of M. tuberculosis
[66].
TLR activation plays an important role in IFNγ produc-
tion by T cells. Active NFκB provided by TLR ligation on
macrophages or dendritic cells induces expression and
secretion of IL-12, a cytokine essential to the TH1 skewing6 Journal of Tropical Medicine
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Figure 2: Arginine (R) is required as a substrate for inducible
nitric oxide synthase (iNOS) in the production of nitric oxide.
Nitric oxide contributes to microbial killing by combining with
reactive oxygen intermediates in the phagolysosome to produce
highly toxic peroxynitrite. Activation of surface TLR2 and TLR1
602I by mycobacterial products, including the 19kDa lipoprotein,
induces transcription of arginase-1 in a CEBPβ-dependent manner.
Arginase-1 reduces substrate availability for iNOS by breaking
down arginine, reducing the production of reactive oxygen species
and favoring mycobacterial survival. TLR1 602S does not traﬃct o
thecellsurface(dashedlines) andthereforedoes not formaTLR1/2
signaling complex which would normally dampen the oxidative
burst.
of CD4+ T-helper cells. Once exposed to IL-12, these cells
begin secreting IFNγ, establishing a positive IFNγ/IL-12
feedback loop (Figure 1). However, stimulation with the
M. tuberculosis 19kDa lipoprotein is suﬃcient to greatly
reduce induction of IFNγ-regulated genes in many cell types,
including murine RAW264.7 cells, mouse bone-marrow-
derived macrophages, human THP-1 cells, and primary
humanmonocytes(Figure 1).Microarrayanalysishasshown
aninhibitionofIFNγ-inducibletranscriptionofIL-12recep-
tor mRNA upon stimulation with mycobacterial lipopro-
teins. This provides direct interference with the IFNγ-IL-12
signaling axis. Further subversion of TLR1/2 signaling is
illustrated by abrogated IFNγ-dependent upregulation of
macrophage activation markers MHCII, CD64, and CD86 in
cells stimulated with either whole mycobacteria or puriﬁed
triacylated lipoproteins. MHCII is a receptor essential for
the activation of adaptive immunity by professional antigen-
presenting cells (APCs). Forced downregulation of MHCII
by mycobacteria corresponds to reduced antigen processing
in murine bone-marrow-derived macrophages and asso-
ciates with a curtailed ability to activate T cells. Phagocyte-
expressedCD86(B7.2)providescostimulatorysignalswhich,
in addition to MHCII, are essential for CD4+ T-helper-
cell activation and survival. Simultaneous inhibition of
CD86 and MHCII by TLR1/2 activation would impart a
major hindrance on recruitment of adaptive help at the
site of infection. Finally, CD64 (FcγRI), a key phagocytic
receptor speciﬁc for IgG-opsonized pathogens, facilitates
pathogen internalization and induction of the oxidative
burst. Downregulation of this receptor could potentially
reduce phagocytic uptake of mycobacteria by macrophages,
dendritic cells, and neutrophils, thereby decreasing pathogen
clearance and generation of peptides for antigen presenta-
tion.
M. tuberculosis also appears to subvert host adaptive
immunity through secretion of ESAT-6. The engagement
of TLR2 by ESAT-6 inhibits IFNγ induction of CTIIA, the
transcriptional coactivator required for MHCII expression
[67]. Furthermore, the TLR2-dependent inhibition of IFNγ
signaling by mycobacterial lipoproteins was shown to act
through a similar mechanism, whereby inhibition of CIITA
blocks induction of many macrophage activation markers
[21, 22, 68].
4.2. Direct Killing of Mycobacteria. Another recent TLR2-
dependentimmunoregulatorymechanismusedbymycobac-
teria has been identiﬁed which aﬀects the macrophage res-
piratory burst [70]. Inducible nitric oxide synthase (iNOS)
generates nitric oxide (NO), a major component of the
phagolysosomal oxidative burst. NO reacts with superoxide,
a product of NADPH oxidase, to generate peroxynitrite,
a powerful oxidant capable of damaging diverse biological
molecules within phagocytized pathogens. iNOS requires
cellular pools of L-arginine to drive catalysis and the avail-
ability of this substrate has been shown to be a rate-limiting
step in production of NO. Arginase-1, a metabolic enzyme
important in the urea cycle, shares arginine as a substrate.
This enzyme participates in the ﬁnal step of the cycle by
metabolizing L-arginine to L-ornithine and urea. Curiously,
it has been reported that during Mycobacterium bovis (BCG)
infection of J774.1 mouse macrophages, the levels of urea
rise with increasing bacterial replication [71]. A recent study
has linked these observations to mycobacterial pathogenesis
by showing that stimulation of primary mouse macrophages
with BCG upregulates levels of both arginase-1 mRNA
and protein [72]. Surprisingly, TLR2 and MyD88 knockout
mice resist upregulation of arginase-1 [72]. In addition,
Arginase-1 knockouts exhibit enhanced NO production in
BCG-infected macrophages and lower bacterial burdens
in an aerosol infection model of M. tuberculosis [72].
Another report found that cell supernatants from BCG-
infected macrophages are capable of inducing arginase-1 in
uninfected neighboring macrophages, an eﬀect dependent
on the production of IL-6 and IL-10 [73]. These data suggest
that mycobacterial stimulation of TLR2 induces arginase-
1, which inhibits the oxidative burst and allows increased
survival within the macrophage endosome (Figure 2).Journal of Tropical Medicine 7
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Figure 3: Schwann cells displaying TLR1 602I and TLR2 are stimulated by the M. leprae 19kDa lipoprotein to commence programmed cell
death. Damage to peripheral nerves, by either direct infection or inﬂammatory ischemia, induces TLR1 expression which, in combination
with TLR2 and mycobacterial products, can amplify apoptotic signals. Upregulation of TLR1 from damage caused by either direct infection
or inﬂammatory ischemia could predispose nerves to further injury, resulting in classical leprosy anesthesis. Cells expressing the traﬃcking-
deﬁcient TLR1 602S may resist this mechanism of nerve damage.
Similar to the inhibition of IFNγ signaling, Arginase-1
mediated immunosuppression was found to be dependent
on CEBP-β [72].
4.3. Nerve Damage. Colonization of Schwann cells by
M. leprae is known to stimulate granuloma formation and
cell-mediated nerve injury [74]. The inﬂux of numerous
adaptive and innate immune cells proximal to an infected
peripheral nerve may produce direct Schwann cell damage
and killing, or indirect death via pressure-induced ischemia.
Immunohistochemistry of skin biopsies from both lepro-
matous and tuberculoid leprosy patients reveals TLR1 and
TLR2 surface expression by multiple cell types, including
Schwann cells [12, 75]. Schwann cell TLR2 is functional as
indicated by the activation of NFκBb ys y n t h e t i cb a c t e r i a l
lipopeptides [75, 76]. TLR2-dependent activation by the
19kDa lipoprotein of M. leprae has also been shown to
induce apoptosis in primary human Schwann cells. This
eﬀect was reduced when cells were incubated with blocking
anti-TLR2 antibodies [75]. Additionally, nerve injury pro-
motes massive upregulation of TLR1, manyfold over most
other Schwann cell-expressed TLRs [76]. Since M. leprae is
capable of activating apoptosis in a TLR2, and presumably
TLR1-dependent manner, it is possible that upregulation of
TLR1 by nerve damage may establish a positive feedback
loop for Schwann cell deterioration (Figure 3). Apoptotic
propertieshavealsobeennotedfortheM.tuberculosis19kDa
antigen. L´ opez et al. revealed a TLR2-dependent induction
of apoptosis in monocyte-derived macrophages stimulated
with the triacylated lipoprotein [77].
5. SNP Protectionagainst
Mycobacterial Infection
Collectively,theabovestudiesconvincinglyhighlighttherole
of TLR1 and TLR2 in mycobacterial pathogenesis. Based on
the established immunosuppressive activity of the TLR1/2
complex following recognition of mycobacterial agonists, it
is not diﬃcult to imagine why a functionally deﬁcient allele
of TLR1 would be advantageous. If TLR1 602S is unable to
gain access to the cell surface, where it is proximal both to
its coreceptor and bacterial ligand, immune evasion through
the TLR1/2 signaling complex would not be achieved by
mycobacteria (Figures 1, 2,a n d3). One could take this a step
further to suggest that TLR1 602S/S homozygous individuals
infected with M. leprae are more likely to develop the less
severe tuberculoid form of the disease. It is intriguing to
note that similar to TLR1, but unlike TLR2, deﬁcient TLR4
functions are generally associated with increased resistance
to M. leprae. If the D299G and T399I SNPs do indeed
confer hyporesponsiveness to TLR4 agonists, the protection
to mycobacteria infection is analogous to the traﬃcking-
deﬁcient TLR1 I602S. At this time no groups have examined
the potential for mycobacteria-derived TLR4 agonists to
induceimmunosuppressiveeﬀectssimilartothoseofTLR1/2
ligands. Such studies could provide a mechanism by which
deﬁcientTLR4signalingprovidesresistancetomycobacteria.
6. Conclusions
Mycobacteria have been signiﬁcant human pathogens for
thousandsofyears.Theearliestknownhumancaseofleprosy8 Journal of Tropical Medicine
Table 1: TLR polymorphisms are organized by receptor, genotype, phenotype, and cohort. The odds ratio (OR) measures the strength of
association between genotype and disease. A ratio less than 1 depicts the degree of protection and a ratio greater than 1 depicts the factor
of increased susceptibility. Reference numbers are included with the associated cohort. RR: reversal reaction; del: deletion; ins: insertion;
VNTR: variable number tandem repeat.
Gene
SNP Reference
Sequence
OR
P value Cohort
Amino acid DNA M. leprae M. tuberculosis
TLR1 I602S A1805G rs5743618 0.48 <0.005 Turkish [38]
0.51 (RR) 0.01 Nepalese [39]
0.31 <0.001 Asian Indian [41]
A/A 2.5 (extrapulmonary) <0.001 African American
[40]
N248S A743G rs4833095 1.24 0.02 Bangladesh [42]
TLR2 ∼ del (–196 to
–174)ins 0.70 0.02 Guinea-Bissau [45]
I/I 0.41 <0.001 Caucasian [45]
∼ VNTR –162 to –100
290bp 0.62 0.02 Ethiopian [46]
288bp 5.83 (RR) 0.001 Ethiopian [46]
0.49 (lepromatous) 0.02 Ethiopian [46]
N199N C597T rs3804099 0.34 (RR) 0.002 Ethiopian [46]
C/C 2.22 0.007 Vietnamese [48]
3.33 (meningitis) 0.004 Vietnamese [48]
R753Q G2258A (A/A) rs5743708 6.04 0.022 Turkish [51]
A/G 1.60 0.59 (χ2) Turkish [51]
5.05 <0.001 Turkish pediatric [52]
TLR4 D299G G896A rs4986790 0.34 <0.001 Ethiopian [31]
2.10 <0.001 Asian Indian [62]
2.00 ∼ Mediterranean
Caucasian [69]
2.80 0.06 Tanzanian [63]
T399I C1196T rs4986791 0.16 <0.001 Ethiopian [31]
TLR9 ∼ G-A rs352143 0.58 0.029 African American
[45]
0.53 0.017 Caucasian [45]
∼ C-T rs5743836 0.54 0.024 African American
[45]
0.50 0.015 Caucasian [45]
has been traced back to over 4000 years ago from East Indian
skeletal remains [78]. Human infection by M. tuberculosis
is arguably even more ancient, as evidenced by 9000-year-
old bone samples from Neolithic settlements testing positive
for TB DNA [79]. The extreme success for a pathogenic
organism such as mycobacteria requires either high rates of
transmission or powerful immunoevasive strategies. Trans-
missibility for tuberculosis is not particularly profound and
only occurs during relatively rare active phases. The likeli-
hood of passing leprosy is equally low; yet these pathogens
are consistently endemic worldwide. Over many decades, the
exquisite mechanisms by which mycobacteria neutralize and
even subvert host defenses have been uncovered, potentially
explaining the impressive eﬀectiveness of these pathogens.
HighlightedinthispaperaretheTLR-mediatedpathways
by which M. leprae and M. tuberculosis are recognized by
the innate immune system. Through many functional and
genetic studies it can be concluded that single nucleotide
polymorphisms in TLRs have the ability to both modify
receptor function and associate with risk of leprosy and
tuberculosis (Table 1). Some investigations have identiﬁed
SNPs which negatively aﬀect TLR signaling and corre-
spondingly induce hyporesponsiveness in immune cells to
these bacteria. In some cases, such as TLR2 in the context
of TB and leprosy and TLR4 in the context of TB, this
abrogated function correlates unsurprisingly with increased
susceptibility of the host to infection. Unexpectedly, how-
ever, this trend is not universal. The I602S polymorphism
of TLR1 inhibits traﬃcking of the receptor to the cell
surface thereby abrogating innate recognition of mycobac-
terial agonists. This functional deﬁciency in TLR1 is not
associated with an increased risk of infection but insteadJournal of Tropical Medicine 9
reduces the likelihood of developing clinical leprosy by
over half. In addition, SNPs which appear to impair TLR4
function (D299G, T399I) reduce the incidence of leprosy
infection by over two-thirds.
Many of the known immunoevasive strategies employed
by mycobacteria operate through TLR activation by bacterial
components. It is intriguing to imagine that mycobacteria
have evolved over the centuries to subvert host responses
in a way that have aided them in their obvious success as
human pathogens. By creating functionally poor responses
to TLR agonists, these SNPs have eﬀectively counteracted
such a strategy. Indeed, the TLR1-6-10 gene cluster has been
identiﬁed as a hotspot of strong positive selection [80, 81]. It
is of interest to note that the geographic distribution of the
TLR1 602I allele, which increases susceptibility to M. leprae
by 1.5 times, is highest in regions where leprosy is most
endemic. Such genetic diversity in TLRs is certain to provide
further important insights into both pathogenesis and host
defense against mycobacteria.
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